, γ-secretase complex proteins (Presenilin 1, Nicastrin) , and downstream target Hes-1. Molecular docking showed that C-B or C-I binds to the ankyrin domain of Notch receptor, which was confirmed using the cellular thermal shift assay. finally, c-B or c-i inhibited tumor xenograft growth in nude mice and decreased the expression of cScmarkers and notch signaling proteins in tumor tissues. together, our study suggests that c-B and c-i inhibit colon cancer growth by inhibiting notch signaling pathway.
www.nature.com/scientificreports www.nature.com/scientificreports/ including marmelin 10 , curcumin and its analogs EF24 and DiFiD [11] [12] [13] , and honokiol 14, 15 . We and other groups have documented anticancer activities of phytochemicals in recent review articles 5, 8, [16] [17] [18] [19] [20] . We also reported that bitter melon extracts affect colon CSCs by disturbing energy homeostasis and inducing autophagy as well as modulating multiple drug resistance proteins 21, 22 . Furthermore, we summarized the chemical constituents of bitter melon and their biological activities 17 . For the present investigation, we selected the cucurbitacin class of compounds belonging to the family of Cucurbitaceae and functions as a defense mechanism against herbivores. They are present in edible human plants such as bitter melon, cucumbers, zucchini, melon, and pumpkin, and as individual compounds are extremely bitter in taste. Several cucurbitacin compounds (Cucurbitacin A-T) have been isolated and evaluated for their pharmacologic properties 23 . Among them, cucurbitacin B (C-B) and cucurbitacin I (C-I) ( Supplementary Fig. 1 ) are interesting compounds present in bitter melon and have the capacity to inhibit cancer cells 23, 24 . C-B has been shown to inhibit the Hippo-YAP and Wnt/β-catenin signaling pathways in CRC and lung cancer, respectively 25 . C-I has been reported to inhibit self-renewal of CD133+cells in thyroid and lung cancer, inhibit STAT3 phosphorylation enhancing chemo and radiosensitivity in medulloblastoma-derived CSCs, and suppress stem-like properties and induce apoptosis in head and neck cancer-derived CD44+-ALDH+cells 26 . Despite potent anticancer effects, detailed mechanistic effects against colon CSCs have not been explored. In the present study, for the first time, we demonstrate the potential of C-B and C-I compounds to inhibit colon CSCs through the Notch-signaling pathway.
Results cucurbitacin B and i inhibits the proliferation of colon cancer cell lines.
We first determined the effect of C-B and C-I ( Supplementary Fig. S1A ) on the proliferation of colon cancer cell lines. Both compounds significantly suppressed the viability of HCT116, SW480 and DLD1 cell lines in a dose-and time-dependent manner, with IC 50 doses ranging from 0.5 to 7.8 µM for different cell lines ( Fig. 1A and Supplementary Fig. S1B ). The antiproliferative effect of the compounds was seen within 24 h and continued to increase over the period of 72 h. We next performed the colony formation assay to understand the long-term effect of these compounds on colon cancer cell lines. The cells were treated with C-B or C-I for 48 h at IC50 and 1/10 IC50 doses, and then grown in fresh media for 10 days. Both compounds significantly inhibited the size and number of colonies formed in HCT116 and SW480 cell lines ( Fig. 1B ,C and Supplementary Fig. S1C ), suggesting that the antiproliferative effects of C-B and C-I are not reversible. These data suggest that C-B and C-I have potent cytotoxic effects on colon cancer cells that are long lasting.
cucurbitacin B and i induces G 2 /M cell cycle arrest.
To further study the antiproliferative effects of C-B and C-I, we analyzed cell cycle transit by flow cytometry. HCT116 and SW480 cells were treated with C-B or C-I for 24 h and 48 h. Both compounds induced G 2 /M cell cycle arrest within 24 hours of treatment ( Supplementary  Fig. S2 ) and cells continued to stay in G 2 /M phase till 48 h ( Fig. 2A ). Western blot analysis of cell cycle-associated proteins, specifically those associated with G 2 /M phase, cyclin B1 and cyclin-dependent kinase 1 (CDK1) were significantly downregulated. The compounds also affected proteins involved in transitioning cells from S-phase (Cyclin A2, CDK2, Wee1, and CDC25C) to G 2 /M confirming cell cycle arrest in HCT116 and SW480 cell lines ( Fig. 2B ). Taken together, these data confirm that C-B and C-I induces a G 2 /M arrest in colon cancer cells that might result in apoptosis.
cucurbitacin B and i induces apoptosis.
The increase in a number of cells in a sub-G 0 stage which results from DNA being fragmented, we infer that C-B and C-I have cytotoxic effects on cells. To confirm this, we used Annexin V/PI staining and observed that when the cells were treated with C-B or C-I, there was an increase in the percentage of cells in the early and late apoptotic stage, when compared to control, untreated cells ( Fig. 3A and Supplementary Fig. S3 ). There was a time-dependent increase in the number of early and late apoptotic cells over 48 h post-treatment. Western blot analysis demonstrated increasing levels of cleaved caspase 3 and cleaved PARP proteins in C-B and C-I treated cells over 48 h (Fig. 3B ). The treatment also increased the expression of pro-apoptotic marker Bax while reducing that of the anti-apoptotic markers Bcl-xL, Mcl-1 and Bcl-2 ( Fig. 3B ). This was further confirmed by caspase 3/7 assays to assess effector caspase activity. Both, C-B and C-I induced a significant upregulation in the activity of effector caspase ( Fig. 3C , p < 0.01). These data suggest that C-B and C-I induce caspase-mediated apoptosis in colon cancer cells.
cucurbitacin B and i inhibits the spheroid formation.
Understanding the mechanisms behind the growth of CSCs is important to develop novel therapeutic agents to get complete elimination of cancer and inhibit recurrence. It is well established that CSCs form spheroids in suspension culture. We observed that both C-B and C-I decreased the size and number of spheroids in HCT116, SW480 and DLD1 cell lines ( Fig. 4A and B and Supplementary Fig. S4 ). To confirm that loss of stem cells resulted in inhibition of spheroids, primary spheroids were dissociated, and equal numbers of cells were cultured in the absence of C-B or C-I. A significant reduction in the number of secondary spheroids was observed ( Fig. 4A and B and Supplementary Fig. S4 ). Furthermore, C-B and C-I treatment significantly downregulated the DCLK1, CD44v and LGR5 expression in both HCT116 and SW480 cells ( Fig. 4C ). These data suggest that C-B and C-I attenuate spheroid growth and CSC marker expression. cucurbitacin B and i downregulate the notch signaling pathway. To further understand the mechanisms by which C-B and C-I to affect stemness, we studied the Notch-signaling pathway. The notch is a transmembrane receptor that is activated by the serial cleavage activities of ADAM/TACE and the γ-secretase complex. These cleavage events result in release of the intracellular domain of the receptor (NICD) that can translocate to the nucleus to activate the expression of its target genes 9 . Treatment with C-B or C-I significantly downregulated the expression of ADAM9, the protein that cleaves ADAM10, and thereby induce cleavage of Notch receptor www.nature.com/scientificreports www.nature.com/scientificreports/ at the extracellular domain ( Fig. 5A) 27 . However, there was no effect on TACE expression ( Fig. 5A ). Both compounds also reduced the levels of all four cleaved Notch receptors (Fig. 5B ). In addition, there was a reduction in the levels of Notch ligands Jagged-1, Jagged-2, DLL1, DLL3 and DLL4 (Fig. 5C ). Moreover, compounds results in the binding to the DNA-binding transcription factor CSL via its RAM and ankyrin domains thereby inducing gene expression 28 . Although, there is limited information available about the involvement of exact amino acid in the binding, Thr56, Arg91, Asp123, Glu190, His221and Asp223 are solvent-exposed and hence (C) Western blot analyses of cells lysates after C-B and C-I treatment showed a significant reduction in cancer stem cell marker DCLK1 (+19 and −19 isoform), DCLK1 (−19 isoform), CD44, and LGR5 protein levels in both HCT116 and SW480 cells. may have functional importance 29 . Our molecular docking analysis showed that C-B and C-I bind to the ankyrin domain of Notch with the binding energy of −6.5 and −7.5 Kcal/mol, respectively. The binding stabilized the interaction by forming hydrogen bonds in the protein cavity comprising functionally important amino acids ( Fig. 6A-E) . We further confirmed the binding results in the SW480 cell line using cellular thermal shift assay. SW480 cell lysates were incubated in the presence or absence of compounds and then subjected to a thermal gradient and assessed for thermal denaturation. Notch-1 protein levels were determined by western blot analysis. We found that thermal denaturation of Notch1 protein occurs at 66 °C, which shifted to 70 °C and 72 °C in the presence of C-B or C-I, respectively (Fig. 6F,G) . This suggests that on interacting with Notch-1, C-B and C-I change the conformation of the protein, making it resistant to thermal denaturation and providing stabilization. Taken together, these data suggest that C-B and C-I interact with Notch-1 and suppress colon cancer growth and stemness.
cucurbitacin B and i inhibits colon cancer xenograft growth in mice. To determine the in vivo
antitumor efficacy of C-B and C-I, we injected 1 × 10 6 HCT116 cells subcutaneously into the flanks of athymic nude mice. Palpable colon cancer xenograft tumors were treated with daily intraperitoneal injection at doses of 1 mg/kg C-B or C-I for 21 days (Supplementary Fig. S5 ). The compounds significantly inhibited tumor growth in HCT116 xenografts compared to vehicle control (DMSO) treated tumors (n = 6, p < 0.01, Fig. 7A,B ). Treatment also resulted in significantly lower tumor volume when compared to control (*p < 0.01). There was a reduction in tumor weight in the C-B and C-I treated animals when compared to controls. There was also a reduction in www.nature.com/scientificreports www.nature.com/scientificreports/ proliferating cells after C-B or C-I treatment as demonstrated by a reduction in PCNA positive cells in xenograft tumors (Fig. 7C ). C-B and C-I treated animals did not experience significant weight loss over the duration of the study, suggesting the compounds administered at 1 mg/kg were well tolerated. To elucidate the molecular www.nature.com/scientificreports www.nature.com/scientificreports/ mechanism of antitumor effects of C-B and C-I, we analyzed xenograft tumors using western blotting. Tumor samples were homogenized and subjected to electrophoresis and subsequently, expression of CSC markers was determined. C-B and C-I downregulated the expression of DCLK1, CD44 and LGR5 in HCT116 tumor samples www.nature.com/scientificreports www.nature.com/scientificreports/ relative to the vehicle control (Fig. 7D ). Further, we analyzed the expression Notch-signaling pathway in HCT116 tumor samples. C-B and C-I treatment reduced the expression of Notch1 protein (Fig. 7E) . However, only C-I showed an even marked reduction in the expression of Nicastrin and Presenilin 1, as well as reductions in downstream signaling proteins such as Hes1 and Cyclin D1 (Fig. 7E ).
Discussion
CRC is a major problem in healthcare, with early-onset across genders becoming an increasing concern 1,2 . The presence of cancer stem cells (CSCs) that are responsible for drug resistance and cancer recurrence remains the major hurdle in the treatment of CRC 5, 6 . This is the first study to identify the effects of C-B and C-I on colon CSCs and Notch pathway.
Phytochemicals are secondary metabolites mainly found in fruits, vegetables, grain, herbs, spices, and edible foods. Phytochemicals generally have a good safety profile, and often exerts health-promoting and disease prevention effects. Several studies have established that the consumption of fruits and vegetables helps with CRC prevention [30] [31] [32] . Here, we studied the effects of cucurbitacin-B (C-B) and -I (C-I), phytochemicals because it is present in bitter melon. We demonstrate that C-B and C-I, phytochemicals present in a number of fruits and vegetables, inhibit cell proliferation. This observation is consistent with published reports describing the anticancer activity of these compounds, at micromolar concentrations, in human colon, breast, lung and ovarian cancer cell lines 25 . Further, we demonstrated that the effects of C-B and C-I are not reversible based on inhibition of colony formation suggesting activity in controlling cancer recurrence. Towards this end, we demonstrate that C-B and C-I treatment decreased tumor growth in vivo.
Interactions between cyclin-dependent kinases (CDKs) and cyclins play an important role in cells transit between different phases of the cycle. In this regard, Cyclin B1:CDC2 is essential for the transition to M-phase, and this is under the control of CDC25 and mitotic checkpoint CHK1/2 proteins 33 . Our data shows that C-B and C-I inhibit the expression of cyclin B1 and CDC2, resulting in G2/M arrest. These results are consistent with previous reports showing C-B induces G 2 /M arrest in SW480 cell line and ATM-mediated DNA damage resulting in reactive oxygen species-dependent manner in a lung cancer cell line 34 .
Inducing apoptosis in the cancer cells has emerged as an effective treatment for cancer. Apoptosis can be induced in response to stress, radiations, growth factor deprivation or DNA damage-induced by cytotoxic agents 35 . A decrease in Bcl2 levels has been reported as a mechanism of C-B-induced apoptosis in laryngeal squamous cell carcinoma and hepatocellular carcinoma 36 . In our study, we not only observed a reduction in Bcl-2, but also in other anti-apoptotic members of the Bcl-2 family, Mcl-1 and Bcl-XL. Given that these two proteins are known to play a significant role in cancer cell survival, and resistance to Bcl2 based therapy, there is a potential for using these compounds in combination with standard-of-care treatment modalities to enhance therapeutic efficacy 37, 38 .
CSCs may, in part, also contribute to therapeutic resistance leading to tumor recurrence and tumor progression. Multiple surface markers have been identified for colorectal CSCs, although almost every one of them appears to be enriching for a population of cells with stem cell-related properties 39 . CD44 is involved in malignant progression, making cells less sensitive to apoptotic signals and chemoresistance in cancer 39, 40 . The standard CD44s isoform has a molecular weight of 85 kDa, while several CD44 variant isoforms (CD44v) have been reported from 85-200 kDa in cancer 41 . Ishimoto et al. 42 have reported the involvement of CD44v in ROS defense and tumor growth in gastrointestinal cancers. Moreover, Banky et al. 43 have shown the existence of multiple CD44 isoforms that play an important role in CRC progression. LGR5 expressing cells appear to induce 5-fluorouracil resistance and recurrence of CRC 39, 44 . DCLK1 expressing cells have been identified as reserve stem cells in the colon 45 . Also, DCLK1 expression in normal and tumor stem cells in the intestine appear to be different and therefore, may be a potential therapeutic target for cancer 46 . Here, we found that both C-B and C-I inhibit colonosphere formation and the expression of all three CSCs markers DCLK1, LGR5, and CD44v, both in cell culture and in vivo in mouse tumor xenograft models. This suggests is that the compounds have effects on both proliferating cells and stem cells, including reserve stem cells marked by DCLK1.
We observed that C-B and C-I treatment downregulated the expression Notch receptors, ligands, γ-secretase complex and target genes. Dysregulation of Notch signaling has been correlated with poor survival, CSC phenotype and EMT resulting in tumor progression in colon cancer 47 . Notch 1 and 2, as well as their ligands, are dysregulated in CRC. Moreover, dysregulation of Notch-3 and ligands, Jagged-1 and Dll-4 have been linked to a more aggressive phenotype in xenografts 48 . Recently, treatment with γ-secretase inhibitors in colon cancer cells having high Notch signaling activity has resulted in a loss of this subpopulation of cells in xenograft tissues 49 .
We utilized molecular docking techniques to study the binding of C-B and C-I with the Notch receptor. C-B and C-I binds with the ankyrin domain and interacted with amino acids exposed to the solvent and thought to be important for the activity. We confirmed the binding to the Notch receptor using the CETSA where we observed the change in protein denaturation temperature upon compound binding to the protein. C-I exhibited lower binding energy in molecular docking and provides better stability to Notch-1 as compared to C-B. The ankyrin repeats in NICD is an interesting site for inhibitor binding because the repeats are involved in protein-protein binding of co-factors such as MAML1, Deltex, p300, PCAF and GCN5 50 . These interactions have been shown to be important for Notch signaling and activity 51, 52 . In addition, NICD binds to DNA-binding transcription factor CSL through these ankyrin repeats to induce gene expression 53 . Hence, targeting the ankyrin domain might be an effective mechanism for suppressing Notch induced activation of gene expression.
In summary, the present study suggests that C-B and C-I inhibit the growth of colon cancer cells both in vitro and in vivo (Fig. 8) . The compounds induce cell cycle arrest and apoptosis as well as inhibit colon CSCs formation. C-B and C-I bind the ankyrin repeats in the Notch 1 receptor resulting in inhibition of signaling. These data suggest that C-B and C-I target Notch signaling pathway and are potential candidates for future lead development Scientific RepoRtS | (2020) 10:1290 | https://doi.org/10.1038/s41598-020-57940-9
www.nature.com/scientificreports www.nature.com/scientificreports/ and optimization. Our future studies will be directed towards the use of C-B and C-I alone and in combination with other treatment modalities against various cancers, to discover and develop analogs with improved potency and druggability properties as well as further elucidating the mechanisms of notch signaling inhibition.
Material and Methods

cells and reagents.
Well-characterized human colon cancer cells HCT116, SW480 and DLD1 (all cell lines obtained from American Type Culture Collection) were used in these studies. The cell lines were grown in DMEM with 4.5 g/L glucose, L-glutamine and sodium pyruvate (Corning, Tewksbury, MA), 10% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO) and 1% antibiotic-antimycotic solution (Corning, Tewksbury, MA) at 37 °C in a humidified atmosphere of 5% CO 2 . All cell lines used in this study were within 20 passages after receipt. Cells were validated by STR analyses. Cucurbitacin B (C-B) and Cucurbitacin I (C-I) was purchased from (Sigma-Aldrich, St. Louis, MO). All methods were performed in accordance with the relevant guidelines and regulations. The protocols were approved by Institutional Animal Care and Use Committees and Institutional Biosafety Committee of the University of Kansas Medical Center. proliferation and colony formation assays. Colon cancer cells (5 × 10 3 cells/well) were plated in 96-well plates, allowed to grow for 24 hours in complete DMEM media containing 10% FBS, and treated with increasing doses of respective vehicle control (DMSO) or C-B and C-I. Cell viability was measured by enzymatic hexosaminidase assay 54 . for colony formation studies, six-well dishes were seeded with 350 viable cells and allowed to grow for 24 h. The cells were then treated with increasing doses of C-B and C-I. Media was replaced after 24 or 48 h, removing drug exposure. The cells were incubated an additional 10 days in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic solution (Mediatech Inc, Herndon, VA). The colonies obtained were washed with PBS and fixed using 10% formalin at room temperature, washed with PBS and stained with Crystal Violet (1% CV in 10% ethanol). The colonies were counted and compared with untreated cells. 
